Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer
Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer simplywall.st
July 2026
Takeda wins approval for first Dengue vaccine in India
Takeda wins approval for first Dengue vaccine in India medwatch.com
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape?
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape? HCP Live